CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.73) by $0.65, MarketWatch Earnings reports.
CNS Pharmaceuticals Trading Up 4.6 %
CNSP traded up $0.09 during trading on Thursday, reaching $2.01. 31,632 shares of the company’s stock were exchanged, compared to its average volume of 1,124,337. CNS Pharmaceuticals has a one year low of $0.61 and a one year high of $6.60. The firm has a fifty day moving average price of $1.54 and a two-hundred day moving average price of $1.82.
Insider Transactions at CNS Pharmaceuticals
In related news, CFO Christopher Downs bought 27,000 shares of the business’s stock in a transaction on Tuesday, August 22nd. The shares were purchased at an average cost of $1.27 per share, with a total value of $34,290.00. Following the acquisition, the chief financial officer now owns 36,772 shares of the company’s stock, valued at $46,700.44. The purchase was disclosed in a filing with the SEC, which is available through this link. 3.88% of the stock is owned by company insiders.
Hedge Funds Weigh In On CNS Pharmaceuticals
CNS Pharmaceuticals Company Profile
CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.
- Five stocks we like better than CNS Pharmaceuticals
- How to Use the MarketBeat Stock Screener
- Is it time to buy the dip in Walmart shares?
- How to Use the MarketBeat Dividend Calculator
- Unlocking AI investment opportunities in healthcare
- Stock Market Upgrades: What Are They?
- New Disney investor propels stock to ranks of best S&P gainers
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.